# US 2016/0354315 A1 · Dosage forms and use thereof

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2016/0354315 A1
- Document ID: US20160354315A1
- Status: Published application
- Kind: A1
- Application number: 15/173,596
- Filed: 2016-06-03
- Published: 2016-12-08
- Earliest claimed: 2015-06-03
- Assignees: Triastek, Inc.
- Applicants: Triastek, Inc.
- Inventors: Xiaoling Li
- Web page: https://patentgrep.com/patent/US20160354315A1

## CPC

- A61K 9/2031: {obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers}
- A61K 9/0065: {Forms with gastric retention, e.g. floating on gastric juice, adhering to gastric mucosa, expanding to prevent passage through the pylorus}
- A61K 9/2027: {obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates}
- A61K 9/2072: {characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms (A61K9/0004, A61K9/0056, A61K9/0065 take precedence)}
- A61K 9/209: {containing drug in at least two layers or in the core and in at least one outer layer}
- A61K 31/192: having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid {(cannabinoids A61K31/658)}
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)

## Abstract

The present disclosure provides a stable solid pharmaceutical dosage form for oral administration. The dosage form includes a substrate that forms at least one compartment and a drug content loaded into the compartment. The dosage form is so designed that the active pharmaceutical ingredient of the drug content is released in a controlled manner.

## Claims

### Claim 1

A dosage form comprising:
a substrate that forms a compartment; and
a drug content loaded into the compartment.

### Claim 2 (depends on 1)

The dosage form of claim 1, wherein the drug content is operably linked to the substrate.

### Claim 3 (depends on 1)

The dosage form of claim 1, wherein the drug content is detached from the substrate.

### Claim 4 (depends on 1)

The dosage form of claim 1, wherein the substrate is made from at least one thermoplastic material.

### Claim 5 (depends on 4)

The dosage form of claim 4, wherein the thermoplastic material is selected from the group consisting of a hydrophilic polymer, a hydrophobic polymer, a swellable polymer, a non-swellable polymer, a porous polymer, a non-porous polymer, an erodible polymer, a non-erodible polymer.

### Claim 6 (depends on 1)

The dosage form of claim 1, wherein the compartment has a shape selected from the group consisting of a pie shape, a cone shape, a pyramid shape, a cylindrical shape, a cubic or cuboidal shape, a triangular or polygonal prism shape, a tetrahedron and a combination thereof.

### Claim 7 (depends on 1)

The dosage form of claim 1, wherein the drug content comprises an active pharmaceutical ingredient (API).

### Claim 8 (depends on 7)

The dosage form of claim 7, wherein the drug content further comprises a medium.

### Claim 9 (depends on 8)

The dosage form of claim 8, wherein the medium is made from a thermoplastic material.

### Claim 10 (depends on 8)

The dosage form of claim 8, wherein the medium has a higher erosion/dissolution rate than the API.

### Claim 11 (depends on 8)

The dosage form of claim 8, wherein the medium has a higher erosion/dissolution rate than the substrate.

### Claim 12 (depends on 1)

The dosage form of claim 1, wherein the compartment has an aperture which is blocked by a plug.

### Claim 13 (depends on 12)

The dosage form of claim 12, wherein the plug is made from a material selected from the group consisting of a water-soluble polymer, an erodible or dissolvable polymer, a wax like material, saccharides or a combination thereof.

### Claim 14

A dosage form comprising:
a substrate that forms at least a first compartment and a second compartment; and
a first drug content loaded into the first compartment and a second drug content loaded into the second compartment.

### Claim 15 (depends on 14)

The dosage form of claim 14, wherein the first drug content is different from the second drug content.

### Claim 16 (depends on 14)

The dosage from of claim 14, wherein the first compartment has a first aperture which is covered by a first plug, and the second compartment has a second aperture which is covered by a second plug.

### Claim 17 (depends on 16)

The dosage form of claim 16, wherein the first plug is longer than the second plug.

### Claim 18 (depends on 16)

The dosage form of claim 16, wherein the first plug has a first permeation rate and the second plug has a second permeation rate, wherein the first permeation rate is different from the second permeation rate.

### Claim 19 (depends on 16)

The dosage form of claim 16, wherein the first plug has a first erosion/dissolution rate and the second plug has a second erosion/dissolution rate, wherein the first erosion/dissolution rate is different from the second erosion/dissolution rate.

### Claim 20 (depends on 14)

The dosage form of claim 14, wherein the first compartment is enclosed by a first wall, and the second compartment is enclosed by a second wall.

### Claim 21 (depends on 20)

The dosage form of claim 20, wherein the first wall is thicker or more permeable than the second wall.

### Claim 22 (depends on 20)

The dosage form of claim 20, wherein the first wall erodes/dissolves faster than the second wall.

### Claim 23

A dosage form comprising:
two or more matrix layers stacked together, wherein at least one of the two or more matrix layers is loaded with at least one drug content, respectively.

### Claim 24 (depends on 23)

The dosage form of claim 23, wherein the two or more matrix layers are detachable from each other.

### Claim 25 (depends on 23)

The dosage form of claim 23, wherein the two or more matrix layers are made from at least one thermoplastic material.

### Claim 26 (depends on 23)

The dosage form of claim 23, wherein the two or more matrix layers have different thickness.

### Claim 27 (depends on 23)

The dosage form of claim 23, wherein the two or more matrix layers have different erosion/dissolution rates.

### Claim 28 (depends on 23)

The dosage form of claim 23, wherein the two or more matrix layers are configured that the loaded each of the at least one drug content is released in an aqueous solution based on a predetermined release profile.

### Claim 29 (depends on 23)

The dosage form of claim 23, wherein the two or more matrix layers comprise a first matrix layer loaded with a first drug content and a second matrix layer loaded with a second drug content and positioned outer than the first matrix layer, such that the second drug content is released prior to the first drug content.
